{"protocolSection":{"identificationModule":{"nctId":"NCT00696787","orgStudyIdInfo":{"id":"3151A4-2003"},"organization":{"fullName":"Wyeth is now a wholly owned subsidiary of Pfizer","class":"INDUSTRY"},"briefTitle":"A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of DVS SR in Adult Female Outpatients With Fibromyalgia Syndrome"},"statusModule":{"statusVerifiedDate":"2013-02","overallStatus":"TERMINATED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-06"},"primaryCompletionDateStruct":{"date":"2009-01","type":"ACTUAL"},"completionDateStruct":{"date":"2009-01","type":"ACTUAL"},"studyFirstSubmitDate":"2008-06-11","studyFirstSubmitQcDate":"2008-06-12","studyFirstPostDateStruct":{"date":"2008-06-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-01-29","resultsFirstSubmitQcDate":"2010-01-29","resultsFirstPostDateStruct":{"date":"2010-02-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-02-20","lastUpdatePostDateStruct":{"date":"2013-02-25","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Wyeth is now a wholly owned subsidiary of Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses."},"conditionsModule":{"conditions":["Fibromyalgia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":125,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.","interventionNames":["Drug: Placebo"]},{"label":"DVS SR","type":"EXPERIMENTAL","description":"In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.","interventionNames":["Drug: Desvenlafaxine Sustained Release (DVS SR)"]},{"label":"Pregabalin","type":"ACTIVE_COMPARATOR","description":"In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.","interventionNames":["Drug: Lyrica® (Pregabalin)"]}],"interventions":[{"type":"DRUG","name":"Desvenlafaxine Sustained Release (DVS SR)","armGroupLabels":["DVS SR"]},{"type":"DRUG","name":"Lyrica® (Pregabalin)","armGroupLabels":["Pregabalin"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline on the Numeric Rating Scale (NRS)","description":"The primary efficacy variable was the change from baseline on the NRS. The primary time point was the average pain score during the last data-analysis-interval of week 8. The baseline score was the average of the NRS scores across the last 7 days of the screening period (just prior to the start of the placebo run-in). The primary efficacy variable was the pain severity score measured on an 11 point NRS on which 0=no pain and 10=worst possible pain.","timeFrame":"Baseline and 8 weeks"}],"secondaryOutcomes":[{"measure":"Change From Baseline on the Numeric Rating Scale (NRS) in the Treatment of Pain Associated With Fibromyalgia in Adult Female Outpatients","description":"The efficacy variable was the change from baseline on the numeric rating scale (NRS). The time point was the average pain score during the last data-analysis-interval of week 8, data analysis interval. The baseline score was the average of the NRS scores across the last 7 days of the screening period (just prior to the start of the placebo run-in). The efficacy variable was the pain severity score measured on an 11 point NRS on which 0=no pain and 10=worst possible pain.","timeFrame":"Baseline and 8 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Fibromyalgia diagnosed according to 1990 American College of Rheumatology criteria\n\nExclusion Criteria:\n\n* Unstable medical or psychological conditions that would compromise the subject's safety or put the subject at greater risk during study participation\n* Other painful conditions that may confound the diagnosis or assessment of fibromyalgia\n* Treatment with other drugs for fibromyalgia with 14 days of study start or during the study","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Wyeth is now a wholly owned subsidiary of Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"city":"Roseville","state":"California","zip":"95661","country":"United States","geoPoint":{"lat":38.75212,"lon":-121.28801}},{"city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"city":"San Diego","state":"California","zip":"92128","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"city":"Santa Ana","state":"California","zip":"92705","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"city":"Tampa","state":"Florida","zip":"33606","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"city":"Decatur","state":"Georgia","zip":"30033","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"city":"Evansville","state":"Indiana","zip":"47714","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"city":"Indianapolis","state":"Indiana","zip":"46260","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"city":"Rockville","state":"Maryland","zip":"20852","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"city":"Lansing","state":"Michigan","zip":"48910","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"city":"Dayton","state":"Ohio","zip":"45408","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"city":"Duncansville","state":"Pennsylvania","zip":"16635","country":"United States","geoPoint":{"lat":40.42341,"lon":-78.4339}},{"city":"Philadelphia","state":"Pennsylvania","zip":"19152","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"city":"Chattanooga","state":"Tennessee","zip":"37421","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"city":"Austin","state":"Texas","zip":"78756","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"city":"San Antonio","state":"Texas","zip":"78205","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"city":"Salt Lake City","state":"Utah","zip":"84102","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"city":"Middleton","state":"Wisconsin","zip":"53562","country":"United States","geoPoint":{"lat":43.09722,"lon":-89.50429}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"After a 7 to 30 day screening period, eligible subjects entered a 7 day single blind placebo run-in period during which placebo responses were assessed.","recruitmentDetails":"Subjects were recruited in the United States from June 2006 to November 2008.","groups":[{"id":"FG000","title":"Placebo","description":"In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor."},{"id":"FG001","title":"DVS SR","description":"In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor."},{"id":"FG002","title":"Pregabalin","description":"In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"42"},{"groupId":"FG002","numSubjects":"43"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"17"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"26"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"Discontinuation by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"14"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Failed to return","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor."},{"id":"BG001","title":"DVS SR","description":"In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor."},{"id":"BG002","title":"Pregabalin","description":"In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"125"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46.90","spread":"12.65"},{"groupId":"BG001","value":"47.83","spread":"10.53"},{"groupId":"BG002","value":"45.42","spread":"12.11"},{"groupId":"BG003","value":"46.70","spread":"11.74"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"125"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline on the Numeric Rating Scale (NRS)","description":"The primary efficacy variable was the change from baseline on the NRS. The primary time point was the average pain score during the last data-analysis-interval of week 8. The baseline score was the average of the NRS scores across the last 7 days of the screening period (just prior to the start of the placebo run-in). The primary efficacy variable was the pain severity score measured on an 11 point NRS on which 0=no pain and 10=worst possible pain.","populationDescription":"The Modified Intent to Treat (MITT) population included all randomized subjects who had taken at least one dose of double-blind test article, who had a baseline primary efficacy evaluation, and who had at least one primary efficacy evaluation on double-blind therapy.","reportingStatus":"POSTED","anticipatedPostingDate":"2010-01","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on scale","timeFrame":"Baseline and 8 weeks","groups":[{"id":"OG000","title":"Placebo","description":"In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor."},{"id":"OG001","title":"DVS SR","description":"In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor."},{"id":"OG002","title":"Pregabalin","description":"In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.98","spread":"0.37"},{"groupId":"OG001","value":"-1.60","spread":"0.37"},{"groupId":"OG002","value":"-1.70","spread":"0.38"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.471","statisticalMethod":"ANCOVA","paramType":"Adjusted mean","paramValue":"-0.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.42","ciUpperLimit":"0.66"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.604","statisticalMethod":"ANCOVA","paramType":"Adjusted mean","paramValue":"-0.28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.33","ciUpperLimit":"0.77"}]},{"type":"SECONDARY","title":"Change From Baseline on the Numeric Rating Scale (NRS) in the Treatment of Pain Associated With Fibromyalgia in Adult Female Outpatients","description":"The efficacy variable was the change from baseline on the numeric rating scale (NRS). The time point was the average pain score during the last data-analysis-interval of week 8, data analysis interval. The baseline score was the average of the NRS scores across the last 7 days of the screening period (just prior to the start of the placebo run-in). The efficacy variable was the pain severity score measured on an 11 point NRS on which 0=no pain and 10=worst possible pain.","populationDescription":"All randomized subjects who had taken at least one dose of double-blind test article, had a baseline primary efficacy evaluation, and had at least one primary efficacy evaluation on double-blind therapy. Subjects who did not complete the study due to its discontinuation were excluded.","reportingStatus":"POSTED","anticipatedPostingDate":"2010-01","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on scale","timeFrame":"Baseline and 8 weeks","groups":[{"id":"OG000","title":"Placebo","description":"In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor."},{"id":"OG001","title":"DVS SR","description":"In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor."},{"id":"OG002","title":"Pregabalin","description":"In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"0.37"},{"groupId":"OG001","value":"-1.64","spread":"0.39"},{"groupId":"OG002","value":"-1.45","spread":"0.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.510","statisticalMethod":"ANCOVA","paramType":"Adjusted mean","paramValue":"-0.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.42","ciUpperLimit":"0.71"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.317","statisticalMethod":"ANCOVA","paramType":"Adjusted mean","paramValue":"-0.55","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.64","ciUpperLimit":"0.54"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Placebo","description":"In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.","seriousNumAffected":0,"seriousNumAtRisk":40,"otherNumAffected":25,"otherNumAtRisk":40},{"id":"EG001","title":"DVS SR","description":"In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.","seriousNumAffected":0,"seriousNumAtRisk":42,"otherNumAffected":25,"otherNumAtRisk":42},{"id":"EG002","title":"Pregabalin","description":"In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.","seriousNumAffected":1,"seriousNumAtRisk":43,"otherNumAffected":32,"otherNumAtRisk":43}],"seriousEvents":[{"term":"Pregnancy and spontaneous abortion","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":42},{"groupId":"EG002","numAffected":1,"numAtRisk":43}]}],"otherEvents":[{"term":"Eye disorders general","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":42},{"groupId":"EG002","numAffected":3,"numAtRisk":43}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":5,"numAtRisk":42},{"groupId":"EG002","numAffected":1,"numAtRisk":43}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":42},{"groupId":"EG002","numAffected":1,"numAtRisk":43}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":42},{"groupId":"EG002","numAffected":2,"numAtRisk":43}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":40},{"groupId":"EG001","numAffected":6,"numAtRisk":42},{"groupId":"EG002","numAffected":3,"numAtRisk":43}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":42},{"groupId":"EG002","numAffected":0,"numAtRisk":43}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":42},{"groupId":"EG002","numAffected":3,"numAtRisk":43}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":42},{"groupId":"EG002","numAffected":5,"numAtRisk":43}]},{"term":"Injury, poisoning and procedural complications general","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":42},{"groupId":"EG002","numAffected":3,"numAtRisk":43}]},{"term":"Metabolism and nutrition disorders general","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":42},{"groupId":"EG002","numAffected":3,"numAtRisk":43}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":42},{"groupId":"EG002","numAffected":0,"numAtRisk":43}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":42},{"groupId":"EG002","numAffected":0,"numAtRisk":43}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":42},{"groupId":"EG002","numAffected":16,"numAtRisk":43}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":42},{"groupId":"EG002","numAffected":5,"numAtRisk":43}]},{"term":"Migraine","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":42},{"groupId":"EG002","numAffected":1,"numAtRisk":43}]},{"term":"Somnolence","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":42},{"groupId":"EG002","numAffected":6,"numAtRisk":43}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":40},{"groupId":"EG001","numAffected":1,"numAtRisk":42},{"groupId":"EG002","numAffected":0,"numAtRisk":43}]},{"term":"Reproductive system and breast disorders general","organSystem":"Reproductive system and breast disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":40},{"groupId":"EG001","numAffected":0,"numAtRisk":42},{"groupId":"EG002","numAffected":0,"numAtRisk":43}]},{"term":"Respiratory, thoracic and mediastinal disorders general","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":40},{"groupId":"EG001","numAffected":2,"numAtRisk":42},{"groupId":"EG002","numAffected":1,"numAtRisk":43}]},{"term":"Skin and subcutaneous tissue disorders general","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":40},{"groupId":"EG001","numAffected":5,"numAtRisk":42},{"groupId":"EG002","numAffected":3,"numAtRisk":43}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication."},"pointOfContact":{"title":"U. S. Contact Center","organization":"Wyeth","email":"clintrialresults@wyeth.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D005356","term":"Fibromyalgia"}],"ancestors":[{"id":"D009135","term":"Muscular Diseases"},{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D012216","term":"Rheumatic Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069583","term":"Pregabalin"}],"ancestors":[{"id":"D005680","term":"gamma-Aminobutyric Acid"},{"id":"D000613","term":"Aminobutyrates"},{"id":"D002087","term":"Butyrates"},{"id":"D000144","term":"Acids, Acyclic"},{"id":"D002264","term":"Carboxylic Acids"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"}]}},"hasResults":true}